Development and Validation of a UV-Vis Spectrophotometric Method for Paracetamol in Tablets under ICH Q2(R2)

Every tablet of paracetamol sold in India carries the promise of a stated dose, and the laboratory method behind that promise must itself be proven — validated — before its numbers mean anything. This project develops and validates a simple UV-Visible spectrophotometric assay for paracetamol in commercial tablets against the framework of ICH Q2(R2) Validation of Analytical Procedures, the internationally harmonised guideline that regulators including the Indian pharmacopoeial system reference. The work begins by scanning paracetamol in the recommended medium to fix the absorbance maximum near 243 nm and confirm Beer's law range, then proceeds through the six validation characteristics the guideline names for a quantitative assay of a drug substance in a finished product: specificity (placebo and excipient interference at the analytical wavelength), linearity (six concentration levels, three replicates each, across 2–12 µg/mL with regression, residual plots and the lack-of-fit test), range justified from linearity, accuracy and precision together, accuracy by standard addition recovery at 80, 100 and 120 percent in triplicate, precision as both repeatability and intermediate precision across days, and detection and quantitation limits by the calibration slope-and-residual approach. Every acceptance criterion is declared in the protocol before analysis, per ICH's expectation of pre-set requirements. The deliverable is a validation report in regulatory style, the raw calibration and recovery datasets, and a critical discussion of why the simple method remains defensible for routine tablet quality control against costlier chromatographic alternatives.

A UV spectrophotometric assay of paracetamol is trivial to run and easy to get wrong in the ways that matter: an impressive calibration coefficient reported as if it were validation; recovery tested only at one level; precision measured once on a single day; detection limits quoted without the calibration statistics that define them; and acceptance criteria chosen after seeing the data. For a small Indian quality-control or teaching laboratory deciding whether the direct-UV method can support tablet assay in place of chromatography, these omissions are decisive, because the answer depends on specificity against the tablet matrix, on accuracy demonstrated by recovery across the range, and on precision whose day-to-day component is known. This project addresses the absence of a complete, protocol-first validation of the direct-UV paracetamol tablet assay under the current ICH Q2(R2) framework — with every acceptance criterion declared before measurement — executed with the instruments of an ordinary postgraduate laboratory and reported in the regulatory style the guideline implies.

Abstract. A UV-Vis spectrophotometric method for assaying paracetamol in tablets was developed and validated against the six validation characteristics of ICH Q2(R2), with acceptance criteria pre-declared in a written protocol. Calibration linearity, recovery-based accuracy, repeatability and intermediate precision, specificity against a placebo, and limit calculations together define the method's validated range for routine quality-control use.

Introduction. Paracetamol is among the highest-volume over-the-counter drugs in India, and tablet dissolution and content uniformity both rest on an assay method. Chromatographic methods are the pharmacopoeial reference, but a teaching-college or small QC laboratory with a serviceable spectrophotometer can run a far simpler direct-UV assay — provided the method is honestly validated for the matrix it will measure. Method validation is also where an M.Sc analytical curriculum turns practical: Beer's law, regression, recovery studies and limits of detection stop being theory and become acceptance criteria that pass or fail.

Literature and gap. Published undergraduate and postgraduate exercises commonly present calibration curves with impressive R² values and stop there, treating validation as R² and a handful of recoveries. ICH Q2(R2) — which replaced R1 effective November 2024 with sharpened expectations, including pre-declared acceptance criteria and multivariate considerations — asks for more: specificity in the presence of the product matrix, precision separated into repeatability and intermediate effects, and detection and quantitation limits derived from the calibration's residual error. The gap this project fills is a complete, protocol-first validation executed at postgraduate level on a real commercial product.

Proposed study. (1) Prepare paracetamol working standard solutions in the selected medium; scan 200–350 nm to fix λmax; confirm Beer's-law bounds by preliminary series. (2) Build the calibration at six levels (2, 4, 6, 8, 10, 12 µg/mL), three independent preparations per level; fit least-squares with residuals, lack-of-fit test and interval statistics. (3) Specificity: measure a placebo mixture of the tablet excipients and a blank at λmax. (4) Accuracy: standard addition to placebo-spiked samples at 80/100/120%, triplicate each; recovery with confidence intervals against 98–102% criterion. (5) Precision: six replicate assay preparations same-day (repeatability) and across three days (intermediate), reported as RSD. (6) LOD and LOQ from calibration residual standard deviation and slope. (7) Apply the validated method to two commercial brands, report assay versus label claim, and write the report in regulatory format.

Feasibility. All work fits a standard college analytical laboratory: a double-beam UV-Vis instrument, IP-grade paracetamol working standard, two marketed brands, Class A glassware. Cost is modest; the schedule fits the semester with the measurement campaign in weeks 6–14 and write-up after data freeze.

In scope. The direct UV-Vis assay of paracetamol from immediate-release commercial tablets: spectral scan and λmax confirmation; calibration and linearity statistics; specificity against a laboratory-prepared placebo of typical excipients (starch, lactose, magnesium stearate, talc); standard-addition accuracy; repeatability and intermediate precision; LOD/LOQ by calibration statistics; application to two marketed brands; the validation report in ICH Q2(R2) style. Statistics computed in Excel and verified in Python.

Out of scope. Chromatographic methods except as cited context; dissolution testing; content-uniformity protocols; forced-degradation stability-indicating studies (flagged as the method's boundary and future work); multi-analyst precision beyond the investigator; and any regulated release testing — this is a research validation, not a batch release.

The study is protocol-first: the validation plan with all acceptance criteria is written and frozen before the measurement campaign.

Phase 1 — method development (weeks 1–4). Prepare paracetamol working standard from IP-grade material; scan 200–350 nm in the selected aqueous medium; confirm λmax near 243 nm; run preliminary concentration series to bound the linear range; fix the working calibration window 2–12 µg/mL.

Phase 2 — protocol freeze (week 5). The written protocol declares: linearity acceptance (R² ≥ 0.999, lack-of-fit p > 0.05, residuals patternless), recovery 98–102% at each spike level, repeatability RSD ≤ 2.0%, intermediate-precision RSD ≤ 3.0%, specificity (placebo absorbance at λmax ≤ 1% of analytical signal), and the LOD/LOQ formulas with their inputs.

Phase 3 — validation campaign (weeks 6–14). Calibration: six levels × three independent preparations, randomised run order. Specificity: blank and placebo scans in triplicate. Accuracy: standard addition to placebo at 80/100/120%, three preparations each. Precision: six replicate assays of one homogenised sample same-day; the full preparation sequence repeated on three days. All raw absorbances logged by hand and transcribed to the dataset under four-eyes check against the instrument printouts.

Phase 4 — analysis (weeks 15–17). Least-squares calibration with residuals, lack-of-fit by ANOVA of replicate levels, recovery means with 95% confidence intervals, RSD computations, LOD/LOQ as 3.3σ/S and 10σ/S. Cross-verify every statistic in Python against Excel.

Phase 5 — application and reporting (weeks 18–20). Assay two brands (ten tablets each, homogenised, triplicate preparations); report content versus label claim with uncertainty; write the report in the ICH-style template; rehearse the viva with the raw-data trail as evidence.

The study's architecture is a chain of evidence from reference material to a regulatory-style report, with the frozen protocol as its spine.

flowchart TD
  A["IP-grade paracetamol<br/>working standard"] --> B["Spectral scan<br/>lambda max ~243 nm"]
  B --> C["Calibration 2-12 ug/mL<br/>6 levels x 3 preps"]
  C --> D["Validation campaign<br/>specificity / accuracy / precision"]
  D --> E["Statistics layer<br/>regression, ANOVA, RSD, LOD-LOQ"]
  E --> F["ICH Q2(R2) report<br/>+ two-brand application"]
  G["Frozen protocol<br/>acceptance criteria"] --> D

Two design features carry the argument. First, every validating measurement is an independent preparation — the three replicates at each level share no volumetric step — so precision reflects the full method, not just instrument noise. Second, the placebo used for specificity and accuracy is prepared from the excipient list of the actual brand under study, which makes the specificity test answer the question the application will actually pose.

Three continuations follow directly. A forced-degradation study (acid, base, oxidative, thermal stress with the degraded samples measured chromatographically in collaboration with an instrument-equipped laboratory) would test whether the UV method's specificity survives degradation, moving it toward stability-indicating status. Extension to a combination product — paracetamol with an excipient or second active absorbing nearby — would exercise the derivative-spectroscopy and multivariate approaches ICH Q2(R2) now explicitly acknowledges. Finally, a small inter-laboratory comparison with a sister college's instrument would upgrade intermediate precision toward reproducibility, the characteristic the guideline defines across laboratories.